OVITRELLE 250mcg Injection/Powder for

What is OVITRELLE 250mcg

OVITRELLE 250mcg is a recombinant human chorionic gonadotropin (hCG) medication used primarily in fertility treatments. It contains the active substance choriogonadotropin alfa, which mimics the natural luteinizing hormone (LH) surge in the body. This hormone is essential for triggering ovulation in women undergoing assisted reproductive techniques (ART), such as in vitro fertilization (IVF).

The product is available in the form of a powder for injection, packaged in 10 vials of lyophilized powder and 10 accompanying solvent vials (1ml each). The contents are to be reconstituted before use.

OVITRELLE is prescribed to:

• Induce final follicular maturation and ovulation in women who have undergone controlled ovarian stimulation.
• Support the luteal phase in certain fertility protocols.
• Assist in timed intercourse or intrauterine insemination (IUI) cycles.

As a recombinant product, it is manufactured using DNA technology, offering a high level of purity and consistent performance. It is typically administered under medical supervision as part of fertility protocols.

How to use OVITRELLE 250mcg

OVITRELLE should only be used under the guidance of a fertility specialist. Proper use ensures effectiveness and reduces risks associated with improper dosing. Here’s how to use the medication:

• Reconstitution:
  • Draw the entire contents of the solvent vial (1ml) into a syringe.
  • Inject the solvent into the vial containing the powder.
  • Gently swirl the vial to dissolve the powder completely. Do not shake.
• Administration:
  • Inject the reconstituted solution subcutaneously, usually in the abdomen or thigh.
  • Use a sterile technique and rotate injection sites to reduce irritation.
  • Administer the dose approximately 24–36 hours before ovulation or oocyte retrieval as advised.
• Monitoring:
  • Ultrasound and blood tests are typically used to time the injection precisely.
  • Follow your fertility clinic’s protocol for exact timing and procedure.

Always use the medication immediately after reconstitution. If not used right away, consult a pharmacist or healthcare provider for storage guidance. Never self-inject unless you have been trained by a healthcare professional.

Mode of Action OVITRELLE 250mcg

OVITRELLE (Choriogonadotropin alfa) works by mimicking the action of the body’s natural LH surge, which is responsible for triggering ovulation in the female reproductive cycle. It promotes reproductive processes essential for successful conception.

• LH Receptor Activation:

  Choriogonadotropin alfa binds to LH/hCG receptors in ovarian follicles, stimulating the final maturation of oocytes (eggs) and initiating the release of a mature egg (ovulation).

• Luteinization:

  It supports the conversion of the ruptured follicle into a corpus luteum, which is critical for progesterone production and implantation.

• Recombinant Technology:

  Being recombinant, OVITRELLE ensures batch consistency and is free from urinary-derived hormone contaminants.

The LH-like activity of OVITRELLE is critical in assisted reproductive protocols, particularly when ovulation does not occur naturally or is being precisely timed for fertility treatments.

OVITRELLE 250mcg Interactions OVITRELLE 250mcg

Although OVITRELLE is generally used within tightly controlled fertility regimens, it is important to be aware of potential drug interactions. These include:

• Other fertility medications:

  When used alongside FSH (follicle-stimulating hormone) or hMG (human menopausal gonadotropin), OVITRELLE enhances follicular development but requires careful monitoring to prevent ovarian hyperstimulation syndrome (OHSS).

• Hormonal contraceptives:

  These can counteract OVITRELLE's effects. Avoid use during treatment cycles unless directed otherwise.

• Anticoagulants:

  In rare cases, if used concurrently with blood thinners, minor bleeding at the injection site may occur more easily.

Always inform your fertility specialist about any medications, supplements, or herbal products you are taking, to ensure a safe and effective treatment plan.

Dosage of OVITRELLE 250mcg

The dosage of OVITRELLE should be individualized based on the fertility protocol being followed. Below is the standard dosing recommendation:

• Usual dose: One 250mcg injection (entire contents of one reconstituted vial) administered subcutaneously.
• Timing: Administer 24 to 36 hours before ovulation is expected, often scheduled after follicular monitoring via ultrasound and hormone levels.
• Follow-up: Timed intercourse or oocyte retrieval should be coordinated closely after the injection for optimal outcomes.
• Repeated doses: OVITRELLE is typically used once per treatment cycle. Additional doses may be used in select protocols under strict medical guidance.

Do not exceed the recommended dosage. Overuse or incorrect timing can lead to complications like ovarian hyperstimulation or reduced efficacy of treatment.

Possible side effects of OVITRELLE 250mcg

Like all medications, OVITRELLE may cause side effects. While many are mild and temporary, some may require medical attention. Common and rare adverse effects include:

• Common side effects:
  • Injection site pain, redness, or swelling
  • Headache
  • Fatigue
  • Abdominal discomfort or bloating
  • Nausea
• Less common:
  • Breast tenderness
  • Mild mood swings or irritability
• Serious (but rare):
  • Ovarian Hyperstimulation Syndrome (OHSS): Characterized by rapid weight gain, severe pelvic pain, shortness of breath, and nausea/vomiting. Requires immediate medical attention.
  • Allergic reaction: Rash, swelling, difficulty breathing (anaphylaxis).
  • Thromboembolic events: Rare blood clotting complications in predisposed individuals.

Report any unusual or severe side effects to your healthcare provider immediately.

OVITRELLE 250mcg Contraindications OVITRELLE 250mcg

Use of OVITRELLE is contraindicated in several situations. It should not be used in patients who:

• Are allergic to choriogonadotropin alfa or any component of the formulation
• Have ovarian, breast, uterine, or pituitary tumors
• Are currently pregnant or breastfeeding
• Have unexplained vaginal bleeding
• Suffer from severe liver, kidney, or cardiac diseases
• Have ovarian enlargement or cysts not due to polycystic ovarian syndrome (PCOS)

Always discuss your medical history in detail with your fertility specialist before beginning treatment with OVITRELLE.

Storage of OVITRELLE 250mcg

Proper storage of OVITRELLE is essential for maintaining its effectiveness:

• Temperature: Store between 2°C and 8°C (36°F to 46°F) in a refrigerator. Do not freeze.
• Short-term storage: It may be kept at room temperature (up to 25°C or 77°F) for up to 30 days. Do not return it to the fridge once removed.
• Light protection: Store in the original packaging to protect from light.
• Use after mixing: Use immediately after reconstitution. Do not store for later use unless explicitly instructed.
• Keep out of reach of children: Store securely to avoid accidental misuse.

Always check the expiry date before use. Do not use if the powder or solution appears discolored or contains particles.